{"id":"NCT01268891","sponsor":"H. Lundbeck A/S","briefTitle":"Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-06","completion":null,"firstPosted":"2010-12-31","resultsPosted":"2013-12-03","lastUpdate":"2013-12-03"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Azilect®","otherNames":["Rasagiline"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Azilect®","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy of a fixed dose of Azilect® (1 mg/day) vs placebo as assessed by the change from baseline in mean total daily OFF time during 18 weeks of treatment in levodopa-treated Parkinson's Disease (PD) patients with motor fluctuations in Korea.","primaryOutcome":{"measure":"Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary","timeFrame":"Baseline and Weeks 6, 10, 14, and 18","effectByArm":[{"arm":"Placebo","deltaMin":-1.24,"sd":0.26},{"arm":"Azilect®","deltaMin":-1.59,"sd":0.25}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3257"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":66},"commonTop":["Dyskinesia","Accidental overdose","Insomnia","Dizziness","Dyspnoea"]}}